# OnCo record nct05607420 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05607420/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05607420", "NCT05607420" ;
  schema:name "Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma"@en ;
  schema:alternateName "NatHaLi-01"@en ;
  schema:description "A phase 1/2 trial of Alemtuzumab in hodgkin lymphoma and non-hodgkin lymphoma, run by Cellectis S.A., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05607420/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05607420> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2022-11-01" ;
  onco:cancers <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/alemtuzumab/> ;
  onco:companies <https://onco.cc/companies/cellectis/> .